<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00096434</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-01817</org_study_id>
    <secondary_id>NCI-2012-01817</secondary_id>
    <secondary_id>CDR0000393224</secondary_id>
    <secondary_id>NCCTG-N0336</secondary_id>
    <secondary_id>N0336</secondary_id>
    <secondary_id>N0336</secondary_id>
    <secondary_id>U10CA025224</secondary_id>
    <nct_id>NCT00096434</nct_id>
  </id_info>
  <brief_title>Sorafenib in Treating Patients With Metastatic Breast Cancer</brief_title>
  <official_title>Phase II Trial of Raf Kinase Inhibitor BAY 43-9006 as Single Oral Agent in Patients With Metastatic Breast Cancer Previously Exposed to Anthracycline and/or Taxane</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      This phase II trial is studying how well sorafenib works in treating patients with metastatic&#xD;
      breast cancer. Sorafenib may stop the growth of tumor cells by blocking the enzymes necessary&#xD;
      for their growth and by stopping blood flow to the tumor.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      I. Determine the tumor response rate in patients with metastatic breast cancer previously&#xD;
      treated with an anthracycline- and/or taxane-containing regimen receiving sorafenib.&#xD;
&#xD;
      II. Assess the toxicity profile of this drug in these patients. III. Determine time to&#xD;
      disease progression and survival time of patients treated with this drug.&#xD;
&#xD;
      IV. Correlate pre-treatment levels of activated ERK1/2 with tumor response in patients&#xD;
      treated with this drug.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients receive oral sorafenib twice daily on days 1-28. Courses repeat every 28 days in the&#xD;
      absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Patients are followed every 6 months until disease progression and then every 3 months for up&#xD;
      to 5 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2004</start_date>
  <primary_completion_date type="Actual">June 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of confirmed tumor responses, graded according to RECIST criteria</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>A confirmed tumor response is defined to be either a CR or PR noted as the objective status on 2 consecutive evaluations at least 4 weeks apart. The tumor response rate is defined as the total number of eligible patients who achieved a complete or partial response according to the RECIST criteria divided by the total number of eligible patients enrolled on study. A 90% confidence interval for the true response rate will be constructed using the Duffy-Santner approach.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to progression</measure>
    <time_frame>Time from registration to disease progression, assessed up to 5 years</time_frame>
    <description>Estimated using the Kaplan-Meier method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival time</measure>
    <time_frame>Time from registration to death, assessed up to 5 years</time_frame>
    <description>Estimated using the Kaplan-Meier method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events, graded according to the NCI-CTC version 3</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>The maximum grade for each type of toxicity will be recorded for each patient at each treatment evaluation. The frequency of each type of toxicity will be determined.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">42</enrollment>
  <condition>Male Breast Cancer</condition>
  <condition>Recurrent Breast Cancer</condition>
  <condition>Stage IV Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive oral sorafenib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sorafenib tosylate</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Arm I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically or cytologically confirmed breast cancer&#xD;
&#xD;
               -  Clinical evidence of metastatic disease&#xD;
&#xD;
          -  Measurable disease&#xD;
&#xD;
          -  HER2-positive or -negative disease&#xD;
&#xD;
               -  If HER2 gene amplified or strongly positive for HER2 by immunohistochemistry,&#xD;
                  patient must have had prior treatment containing trastuzumab (Herceptin®) unless&#xD;
                  contraindicated&#xD;
&#xD;
          -  Previously treated with anthracycline- and/or taxane-containing regimen in the&#xD;
             neoadjuvant, adjuvant, or metastatic setting&#xD;
&#xD;
          -  Candidate for first- or second-line chemotherapy for metastatic disease&#xD;
&#xD;
          -  Core block or tumor slides of the primary or metastatic tumor available&#xD;
&#xD;
          -  No known brain metastases&#xD;
&#xD;
          -  Hormone receptor status:&#xD;
&#xD;
               -  Not specified&#xD;
&#xD;
          -  Male or female&#xD;
&#xD;
          -  Performance status - ECOG 0-1&#xD;
&#xD;
          -  At least 3 months&#xD;
&#xD;
          -  WBC ≥ 3,000/mm^3&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,500/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin ≥ 8.5 g/dL&#xD;
&#xD;
          -  No evidence of bleeding diathesis&#xD;
&#xD;
          -  Bilirubin ≤ 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  AST ≤ 3 times ULN&#xD;
&#xD;
          -  Alkaline phosphatase ≤ 3 times ULN&#xD;
&#xD;
          -  PT normal&#xD;
&#xD;
          -  PTT normal&#xD;
&#xD;
          -  INR normal&#xD;
&#xD;
          -  Creatinine ≤ 1.5 times ULN&#xD;
&#xD;
          -  Calcium normal&#xD;
&#xD;
          -  No symptomatic congestive heart failure&#xD;
&#xD;
          -  No unstable angina pectoris&#xD;
&#xD;
          -  No cardiac arrhythmia&#xD;
&#xD;
          -  No uncontrolled hypertension&#xD;
&#xD;
          -  No gastrointestinal tract disease that would preclude taking oral medication&#xD;
&#xD;
          -  No active peptic ulcer disease&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No other malignancy within the past 5 years except adequately treated basal cell or&#xD;
             squamous cell skin cancer&#xD;
&#xD;
          -  No history of allergic reaction attributed to compounds of similar chemical or&#xD;
             biological composition to sorafenib or other study agents&#xD;
&#xD;
          -  No ongoing or active infection&#xD;
&#xD;
          -  No psychiatric illness or social situation that would preclude study participation&#xD;
&#xD;
          -  No other uncontrolled illness&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  More than 4 weeks since prior immunotherapy&#xD;
&#xD;
          -  No concurrent anticancer immunotherapy&#xD;
&#xD;
          -  No concurrent bevacizumab&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) and&#xD;
             recovered&#xD;
&#xD;
          -  No more than 1 prior chemotherapy regimen for metastatic disease&#xD;
&#xD;
          -  No concurrent anticancer chemotherapy&#xD;
&#xD;
          -  Prior hormonal therapy in the neoadjuvant, adjuvant, or metastatic setting is allowed&#xD;
&#xD;
          -  No concurrent anticancer hormonal therapy&#xD;
&#xD;
          -  No prior radiotherapy to ≥ 25% of the bone marrow&#xD;
&#xD;
          -  More than 4 weeks since prior radiotherapy&#xD;
&#xD;
          -  More than 4 weeks since prior major surgery&#xD;
&#xD;
          -  No prior surgical procedure that would affect gastrointestinal absorption&#xD;
&#xD;
          -  No other concurrent drugs that target vascular endothelial growth factor (VEGF) or&#xD;
             VEGF receptors&#xD;
&#xD;
          -  No concurrent antiretroviral therapy for HIV-positive patients&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
&#xD;
          -  No other concurrent anticancer therapy&#xD;
&#xD;
          -  No concurrent cytochrome P450 enzyme-inducing antiepileptic drugs, including any of&#xD;
             the following:&#xD;
&#xD;
               -  Phenytoin&#xD;
&#xD;
               -  Carbamazepine&#xD;
&#xD;
               -  Phenobarbital&#xD;
&#xD;
          -  No concurrent rifampin&#xD;
&#xD;
          -  No concurrent Hypericum perforatum (St. John's wort)&#xD;
&#xD;
          -  No concurrent therapeutic anticoagulation&#xD;
&#xD;
               -  Concurrent prophylactic anticoagulation (i.e., low-dose warfarin) for venous or&#xD;
                  arterial devices is allowed&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edith Perez</last_name>
    <role>Principal Investigator</role>
    <affiliation>North Central Cancer Treatment Group</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>North Central Cancer Treatment Group</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <study_first_submitted>November 9, 2004</study_first_submitted>
  <study_first_submitted_qc>November 9, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 10, 2004</study_first_posted>
  <last_update_submitted>October 7, 2013</last_update_submitted>
  <last_update_submitted_qc>October 7, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 8, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Breast Neoplasms, Male</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sorafenib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

